p53 mutations in human cholangiocarcinoma: A review

Liver International

Volumn 25, Issue 4, 2005, Pages 704-716

  Khan, Shahid A ^a   Thomas, Howard C ^a   Toledano, Mireille B ^a   Cox, I Jane ^a   Taylor Robinson, Simon D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cholangiocarcinoma; Mutations; p53

Indexed keywords

CARCINOGEN; PROTEIN P53;

BILE DUCT CARCINOMA; BILE DUCT TUMOR; CANCER MORTALITY; CARCINOGENESIS; DATA ANALYSIS; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; HUMAN; IMMUNOHISTOCHEMISTRY; INDUSTRIALIZATION; REVIEW; TUMOR SUPPRESSOR GENE;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 22844431612     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01106.x     Document Type: Review

References (57)

1. Taylor-Robinson S D, Foster G R, Arora S, Hargreaves S, Thomas H C. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-3.
2. Taylor-Robinson S D, Toledano M B, Arora S, Keegan T J, Hargreaves S, Beck A, Khan S A, Elliott P, Thomas H C. Increase in mortality rates for intrahepatic cholangiocarcinoma in England & Wales 1968-1998. Gut 2001; 48: 816-20.
3. Khan S A, Taylor-Robinson S D, Toledano M B, Beck A, Elliott P, Thomas H C. Changing international trends in mortality rates for liver, biliary and pancreatic tumours 1979-1997. J Hepatol 2002; 37: 806-13.
4. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-7.
5. Shaib Y H, Davila J A, McGlynn K, El-Serag H B. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40: 472-7.
6. IARC, International Agency for Research on Cancer, p53 Database. 2002. (www.iarc.fr/p53).
7. Lodish H, Berk A, Zipursky S L, Matsudaira P, Baltimore D, Darnell J. In Molecular Cell Biology, 4th edn. San Francisco: W H Freeman, 2000.
8. Harris C C. Structure and function of the p53 tumor suppressor gene. J Natl Cancer Inst 1996; 88: 1442-5.
9. McKusick VA, ed. OMIM™ (Online Mendelian Inheritance in Man) Database. National Centre for Biotechnology Information, 2002 (http://www.ncbi.nlm.nih.gov/Omim).
10. Olivier M, Eeles R, Hollstein M, Khan M A, Harris C C, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-14.
11. Sidransky D, Hollstein M. Clinical implications of the p53 gene. Annu Rev Med 1996; 47: 285-301.
12. Hollstein M, Sidransky D, Vogelstein B, Harris C C. p53 mutations in human cancers. Science 1991; 253: 49-53.
13. Evans S C, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 1997; 3: 390-5.
14. Furubo S, Harada K, Shimonishi T, Katayanagi K, Tsui W, Nakanuma Y. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology 1999; 35: 230-40.
15. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999; 18: 7690-700.
16. Ganong W F. Review of Medical Physiology, 19th edn. New York: McGraw-Hill Education, 1999.
17. Arora D S, Ramsdale J, Lodge J P, Wyatt J I. p53 but not bcl-2 is expressed by most cholangiocarcinomas: a study of 28 cases. Histopathology 1999; 34: 497-501.
18. Terada T, Shimizu K, Izumi R, Nakanuma Y. Methods in pathology. p53 expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections. Mod Pathol 1994; 7: 249-52.
19. Bergquist A, Glaumann H, Stal P, Wang G S, Broome U. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma. J Intern Med 2001; 249: 69-75.
20. Boberg K M, Schrumpf E, Bergquist A, Broome U, Pares A, Remotti H, Schjolberg A, Spurkland A, Clausen O P. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol 2000; 32: 374-80.
21. Rizzi P M, Ryder S D, Portmann B, Ramage J K, Naoumov N V, Williams R. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 1996; 38: 265-8.
22. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, Yoshimura A, Ko S, Kin T, Yagura K, et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995; 109: 1612-7.
23. Kang Y K, Kim W H, Lee H W, Lee H K, Kim Y I. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999; 79: 477-83.
24. Washington K, Gottfried M R. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver 1996; 16: 99-104.
25. Terada T, Nakanuma Y. Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewis(y) and p53) in human cholangiocarcinomas and hepatocellular carcinomas. Pathol Int 1996; 46: 764-70.
26. Sturm P D, Baas I O, Clement M J, Nakeeb A, Johan G, Offerhaus A, Hruban R H, Pitt H A. Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area. Int J Cancer 1998; 78: 695-8.
27. Kamikawa T, Amenomori M, Itoh T, Momoi H, Hiai H, Machinami R, Ishikawa Y, Mori T, Shimahara Y, Yamaoka Y, Fukumoto M. Analysis of genetic changes in intrahepatic cholangiocarcinoma induced by thorotrast. Radiat Res 1999; 152: S118-24.
28. Thamavit W, Pairojkul C, Tiwawech D, Shirai T, Ito N. Strong promoting effect of Opisthorchis viverrini infection on dimethylnitrosamine-initiated hamster liver. Cancer Lett 1994; 78: 121-5.
29. Srivatanakul P, Ohshima H, Khlat M, Parkin M, Sukaryodhin S, Brouet I, Bartsch H. Opisthorchis viverrini infestation and endogenous nitrosamines as risk factors for cholangiocarcinoma in Thailand. Int J Cancer 1991; 48: 821-5.
30. Parkin D M, Ohshima H, Srivatanakul P, Vatanasapt V. Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev 1993; 2: 537-44.
31. Kiba T, Tsuda H, Pairojkul C, Inoue S, Sugimura T, Hirohashi S. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog 1993; 8: 312-8.
32. Tullo A, D'Erchia A M, Honda K, Kelly M D, Habib N A, Saccone C, Sbisa E. New p53 mutations in hilar cholangiocarcinoma. Eur J Clin Invest 2000; 30: 798-803.
33. Torre G, Pasquini G, Pilotti S, Alasio L, Civelli E, Cozzi G, Milella M, Salvetti M, Pierotti MA, Severini A. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas. Diagn Mol Pathol 2000; 9: 41-6.
34. Jonas S, Springmeier G, Tauber R, Wiedenmann B, Lobeck H, Gessner R, Kreft B, Kling N, Moelling K, Neuhaus P. p53 mutagenesis in Klatskin tumors. Hum Pathol 1998; 29: 955-60.
35. Sturm PD, Bass IO, Clement MJ, Nakeeb A, Johan G, Offerhaus A, Hruban RH, Pitt HA. Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area. Int J Cancer 1998; 78: 695-8.
36. Momoi H, Itoh T, Nozaki Y, Arima Y, Okabe H, Satoh S, Toda Y, Sakai E, Nakagawara K, Flemming P, Yamamoto M, Shimahara Y, Yamaoka Y, Fukumoto M. Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. J Hepatol 2001; 35: 235-44.
37. Petmitr S, Pinlaor S, Thousungnoen A, Karalak A, Migasena P. K-ras oncogene and p53 gene mutations in cholangiocarcinoma from Thai patients. Southeast Asian J Trop Med Public Health 1998; 29: 71-5.
38. Imai Y, Oda H, Arai M, Shimizu S, Nakatsuru Y, Inoue T, Ishikawa T. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hepatocellular-cholangiocellular carcinomas. Jpn J Cancer Res 1996; 87: 1056-62.
39. Ishikawa Y, Wada I, Fukumoto M. Alpha-particle carcinogenesis in Thorotrast patients: epidemiology, dosimetry, pathology, and molecular analysis. J Environ Pathol Toxicol Oncol 2001; 20: 311-5.
40. Iwamoto K S, Fujii S, Kurata A, Suzuki M, Hayashi T, Ohtsuki Y, Okada Y, Narita M, Takahashi M, Hosobe S, Doishita K, Manabe T, Hata S, et al. p53 mutations in tumor and non-tumor tissues of thorotrast recipients: a model for cellular selection during radiation carcinogenesis in the liver. Carcinogenesis 1999; 20: 1283-91.
41. Wada I, Horiuchi H, Mori M. Ishikawa Y, Fukumoto M, Mori T, Kato Y, Kitagawa T, Machinami R. High rate of small TP53 mutations and infrequent loss of heterozygosity in malignant liver tumors associated with thorotrast: implications for alpha-particle carcinogenesis. Radiat Res 1999; 152: S125-7.
42. Pfeifer G P. p53 mutational spectra and the role of methylated CpG sequences. Mutat Res 2000; 30; 450: 155-66.
43. Smela M E, Currier S S, Bailey E A, et al. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis 2001; 22: 535-45.
44. Sylla A, Diallo M S, Castegnaro J, Wild C P. Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach. Mutat Res 1999; 428: 187-96.
45. Ross R K, Yuan J M, Yu M C, Wogan G N, Qian G S, Tu J T, Groopman J D, Gao Y T, Henderson B E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943-6.
46. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-31.
47. Hsu I C, Metcalf R A, Sun T, Welsh J A, Wang N J, Harris C C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-8.
48. Cong W M, Bakker A, Swalsky P A, Raja S, Woods J, Thomas S, Demetris A J, Finkelstein S D. Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: a molecular genetic and clinicopathological study. J Cancer Res Clin Oncol 2001; 127: 187-92.
49. Hussain S P, Hofseth L J, Harris C C. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 2001; 34: S7-15.
50. Cartegni L, Chew S L, Krainer A R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002; 3: 285-98.
51. Kuivenhoven J A, Weibusch H, Pritchard P H, Funke H, Benne R, Assmann G, Kastelein J J. An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease). J Clin Invest 1996; 98: 358-64.
52. Webb J C, Patel D D, Shoulders C C, Knight B L, Soutar A K. Genetic variation at a splicing branch point in intron 9 of the low density lipoprotein (LDL)-receptor gene: a rare mutation that disrupts mRNA splicing in a patient with familial hypercholesterolaemia and a common polymorphism. Hum Mol Genet 1996; 5: 1325-31.
53. Maslen C, Babcock D, Raghunath M, Steinmann B. A rare branch-point mutation is associated with missplicing of fibrillin-2 in a large family with congenital contractural arachnodactyly. Am J Hum Genet 1997; 60: 1389-98.
54. Janssen R J, Wevers R A, Haussler M, Luyten J A, Steenbergen-Spanjers G C, Hoffmann G F, Nagatsu T, Van den Heuvel L P. A branch site mutation leading to aberrant splicing of the human tyrosine hydroxylase gene in a child with a severe extrapyramidal movement disorder. Ann Hum Genet 2000; 64: 375-82.
55. Ishii S, Nakao S, Minamikawa-Tachino R, Desnick R J, Fan J Q. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet 2002; 70: 994-1002.
56. Hernandez-Boussard T, Montesano R, Hainaut P. Sources of bias in the detection and reporting of p53 mutations in human cancer: analysis of the IARC p53 mutation database. Genet Anal 1999; 14: 229-33.
57. Vineis P. Molecular epidemiology of cancer. In: Alison MR, ed. The Cancer Handbook. Hampshire, UK: Nature Publishing Group, 2002; 377-387 (Chapter 27).